MMSL 2016, 85(1):13-18 | DOI: 10.31482/mmsl.2016.003

ORLISTAT AND PHENTERMINE IN WEIGHT LOSS IN SELECTED CZECH POPULATIONOriginal article

Vladimír Pavlík ORCID...1, Jana Fajfrová ORCID...1*, Jan M. Horáček ORCID...1, Václav Šafka ORCID...1, Pavla Krutišová ORCID...1, Miroslav Urban1, Peter Urban2, Jana Gazdačková3, Petr Navrátil4
1 Department of Military Internal Medicine and Military Hygiene, Faculty of Military Health Sciences, University of Defence, Hradec Králové
2 First Faculty of Medicine, Charles University, Prague
3 Language Centre, Faculty of Military Health Sciences, University of Defence, Hradec Králové
4 Military Medical Department, Division of Support, Ministry of Defence, Prague

Aim: To describe effectiveness of orlistat and phentermine in soldiers of the Armed Forces of the Czech Republic.

Methods: In ambulatory patients, some anthropometric and biochemical parameters were compared before administration with 120 mg of orlistat three times a day or 15 mg of phentermine once a day. The same parameters were compared after a three-month therapy. This group included 289 patients (238 males and 51 females) who were administered the same dose of orlistat or phentermine for the entire period of time.

Results: Statistically significant weight loss in both genders, on average by 4.6 ± 4.2 kg in males and by 5.3 ± 4.3 kg in females, was observed in patients taking orlistat within three months. Statistically significant weight loss, on average by 6.5 ± 6.0 kg in males and by 5.2 ± 4.3 kg in females, was also observed in patients taking phentermine for the same period of time. As for monitored biochemical parameters, a decrease of total cholesterol, HDL cholesterol and glucose at a statistically significant level (p<0.05) was observed in the group of females, the same statistically significant decrease, but in triglycerides, was proved in the group of males. Then a decrease of total cholesterol and increase of HDL cholesterol at a statistically significant level (p<0.001) was observed in the group of males.

Conclusion: We can state that in our patients we have proven a positive effect of orlistat or phentermine substitution on their weight reduction.

Keywords: Anti-obesity agents; Pharmacotherapy of obesity; Weight reduction; Health support; Czech Armed Forces

Received: February 11, 2016; Revised: February 19, 2016; Published: March 4, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pavlík, V., Fajfrová, J., Horáček, J.M., Šafka, V., Krutišová, P., Urban, M., ... Navrátil, P. (2016). ORLISTAT AND PHENTERMINE IN WEIGHT LOSS IN SELECTED CZECH POPULATION. MMSL, 85(1), 13-18. doi: 10.31482/mmsl.2016.003
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Frühbeck, G.; Toplak, H.; Woodward, E.; Yumuk, V.; Maislos, M.; Oppert, JM. Executive Committee of the European Association for the Study of Obesity. Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes. Facts. 2013, 6(2), 117-120. Go to original source... Go to PubMed...
    2. James, WP. The epidemiology of obesity: the size of the problem. J. Intern. Med. 2008, 263, 336-352. Go to original source... Go to PubMed...
    3. Ginter, E.; Simko, V. Adult obesity at the beginning of the 21st century: epidemiology, pathophysiology and health risk. Bratisl. Med. J. 2008, 109, 224-230.
    4. Fajfrová, J., Pavlík, V., Psutka, J., Husarová, M., Krutišová, P., Fajfr, M. Prevalence of overweight and obesity in professional soldiers of the Czech army over a 11-year period. Vojnosanitetski pregled. 2016 OnLine-First (00):112-112. DOI:10.2298/VSP141120112F Go to original source...
    5. Chaloupka, J.; Býma, S.; Hlúbik, P. Advanced Preventive Care Program in the Army of the Czech Republic. Voj. Zdrav. Listy. 2000, 69(2), 57-62 (in Czech).
    6. Pavlík, V.; Fajfrová, J.; Husárová, M.; Hlúbik, P. Prevention of overweight and obesity in the Army of the Czech Republic. Hygiena. 2011, 56(3), 85-87 (in Czech).
    7. Hainer, V. Comparative efficiency and safety of pharmacological approaches to the management of obesity. Diabetes Care. 2011, 34, 349-355. Go to original source... Go to PubMed...
    8. Bray, GA. Medical therapy for obesity. Mt. Sinai. J. Med. 2010, 77(5), 407-17. Go to original source... Go to PubMed...
    9. Matoulek, M. The manual of practical obesitology. NOL, Prague 2014, p 11-38 (in Czech).
    10. Van Gaal, LF.; Broom, JI.; Enzi, G.; Toplak, H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6 - month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur. J. Clin. Pharmacol. 1998, 54, 125-132. Go to original source...
    11. Derosa, G.; Maffioli, P.; Salvadeo, SA.; Ferrari, I.; Gravina, A.; Mereu, R. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert. Opin. Pharmacother. 2010, 11, 1971-82. Go to original source... Go to PubMed...
    12. Allison, DB.; Gadde, KM.; Garvey, WT.; Peterson, CA.; Schwiers, ML.; Najarian, T. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial. Obesity. 2012, 20, 330-42. Go to original source... Go to PubMed...
    13. Gadde, KM.; Day WW. Low-dose, controlledrelease phentermin/topiramate for reduction of weight. Obesity reviews 2010, 11(1), 42-43.
    14. Hollander, P.; Elbein, SC.; Hirsch, I. Role of orlistat in the treatment of obese patients with type 2 diabetes. A one year randomized double blind study. Diab care. 1998, 21, 1288-1294. Go to original source... Go to PubMed...
    15. Sjostrom, L.; Rissanen, A.; Andersen, T. Randomized placebo controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat study Group. Lancet. 1998, 352, 167-172. Go to original source...
    16. Zhi, J.; Melia, AT.; Guerciolini, R. Retrospective population based analysis of the dose response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin. Pharmacol. Ther. 1994, 56, 82-85. Go to original source... Go to PubMed...
    17. Bays, HE.; Gadde, KM. Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity. Drugs Today. 2011, 47, 903-914. Go to original source... Go to PubMed...
    18. Waden, TA.; Berkowitz, RI.; Womble, LG.; Sarwer, DB.; Phelan, S.; Cato, RK. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 2005, 353, 2111-2116. Go to original source... Go to PubMed...
    19. Ornellas, T.; Chavez, B. A New Approach to Weight Loss in Obese Adults. Pharmacy and Therapeutics. 2011, 36, 255-256, 261-262.
    20. Li, Z.; Maglione, M.; Tu, W.; Mojica, W.; Arterburn, D.; Shugarman, LR. Pharmacologic treatment of obesity. Ann. Intern. Med. 2005, 142, 532-538. Go to original source...
    21. Holes-Lewis, KA.; Malcolm, R.; O'Neil, PM. Pharmacotherapy of obesity: clinical treatments and considerations. Am. J. Med. Sci. 2013, 345, 284-288. Go to original source... Go to PubMed...

    Return to the content